Glucose-6-phosphate isomerase deficiency results in mTOR activation, failed translocation of lipin 1α to the nucleus and hypersensitivity to glucose: Implications for the inherited glycolytic disease  by Haller, Jorge F. et al.
Biochimica et Biophysica Acta 1812 (2011) 1393–1402
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbadisGlucose-6-phosphate isomerase deﬁciency results in mTOR activation, failed
translocation of lipin 1α to the nucleus and hypersensitivity to glucose: Implications
for the inherited glycolytic disease
Jorge F. Haller a, Sarah A. Krawczyk b, Lubov Gostilovitch a, Barbara E. Corkey b, Raphael A. Zoeller a,⁎
a Department of Physiology and Biophysics, Boston University School of Medicine, USA
b Department of Medicine and Biochemistry, Boston University School of Medicine, USAAbbreviations: GPI, glucose-6-phosphate isomeras
F6P, fructose-6-phosphate; PAP, phosphatidate phosph
DAG, diacylglycerol; PE, phosphatidylethanolamine;
triglycerides; PPAR, peroxisome proliferator-activated re
ovary; mTOR, mammalian target of rapamycin;
32
Pi, [
32
ﬂuorescent protein; FBS, fetal bovine serum; PDK1,
kinase-1; S6K, S6 Kinase; AMPK, adenosine monophosp
PI3K, phosphoinositide 3-kinase; GSK-3β, glycogen sy
phosphatase and tensin homolog; NHSA, non-spherocy
⁎ Corresponding author at: 700 Albany St. W-302 B
02215. Tel.: +1 617 638 4010; fax: +1 617 638 4041.
E-mail address: rzoeller@bu.edu (R.A. Zoeller).
0925-4439/$ – see front matter © 2011 Elsevier B.V. Al
doi:10.1016/j.bbadis.2011.07.007a b s t r a c ta r t i c l e i n f oArticle history:
Received 6 December 2010
Received in revised form 10 July 2011
Accepted 12 July 2011
Available online 23 July 2011
Keywords:
Glucose-6-phosphate isomerase deﬁciency
Mutant
Phospholipid biosynthesis
Lipin 1
Lipodystrophy
Non-spherocytic anemiaInherited glucose-6-phosphate isomerase (GPI) deﬁciency is the second most frequent glycolytic
erythroenzymopathy in humans. Patients present with non-spherocytic anemia of variable severity and
with neuromuscular dysfunction. We previously described Chinese hamster (CHO) cell lines with mutations
in GPI and loss of GPI activity. This resulted in a temperature sensitivity and severe reduction in the synthesis
of glycerolipids due to a reduction in phosphatidate phosphatase (PAP). In the current article we attempt to
describe the nature of this pleiotropic effect. We cloned and sequenced the CHO lipin 1 cDNA, a gene that
codes for PAP activity. Overexpression of lipin 1 in the GPI-deﬁcient cell line, GroD1 resulted in increased PAP
activity, however it failed to restore glycerolipid biosynthesis. Fluorescence microscopy showed a failure of
GPI-deﬁcient cells to localize lipin 1α to the nucleus. We also found that glucose-6-phosphate levels in GroD1
cells were 10-fold over normal. Lowering glucose levels in the growth medium partially restored glycerolipid
biosynthesis and nuclear localization of lipin 1α. Western blot analysis of the elements within the mTOR
pathway, which inﬂuences lipin 1 activity, was consistent with an abnormal activation of this system.
Combined, these data suggest that GPI deﬁciency results in an accumulation of glucose-6-phosphate, and
possibly other glucose-derived metabolites, leading to activation of mTOR and sequestration of lipin 1 to the
cytosol, preventing its proper functioning. These results shed light on the mechanism underlying the
pathologies associated with inherited GPI deﬁciency and the variability in the severity of the symptoms
observed in these patients.e; G6P, glucose-6-phosphate;
atase; PA, phosphatidic acid;
PC, phosphatidylcholine; TG,
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P]orthophosphate; GFP, green
phosphoinositide-dependent
hate activated protein kinase;
nthase kinase 3 beta; PTEN,
tic hemolytic anemia
oston University, Boston, MA
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Glucose-6-phosphate isomerase (GPI, EC 5.3.1.9) is a cytosolic, non
rate-limiting enzyme in glycolysis. It catalyzes the reversible isomeriza-
tion of glucose-6-phosphate to fructose-6-phosphate. Mutations in GPI
are the secondmost frequent cause of inherited glycolytic enzymopathy
in humans [1]. This autosomal recessive disorder is characterized by a
non-spherocytic anemia of variable severity which can present with
neuromuscular dysfunctions deﬁned by muscle weakness and mentalretardation [2]. Patients andmicewith the sameGPImutations can have
different outcomes in the severity of the anemia or the neuromuscular
dysfunction [2–4]. Unfortunately, the mechanism by which GPI
deﬁciency causes these symptoms is not well understood [1,2]. Hence,
the current therapeutics for these patients involve splenectomy and
blood transfusions reserved for the most severe hemolytic cases [1,2].
We have recently isolated three independent CHO (Chinese
hamster ovary) derived cell lines, each of which presented a different
point mutation in GPI [5]. These cell lines displayed low GPI activity,
were all deﬁcient in the synthesis of glycerolipids, and had decreased
phosphatidate phosphatase (PAP, EC 3.1.3.4) activity (Fig. 1). They
also presented a temperature sensitive phenotype; these cells were
unable to grow at 40 °C [5]. Expression of wild-type GPI in these cells
recovered glycerolipid biosynthesis and PAP activity and corrected the
temperature dependent phenotype, demonstrating a dependence of
PAP activity and glycerolipid biosynthesis on GPI activity through an,
as yet, unknown mechanism.
PAP is crucial for animal cell glycerolipid biosynthesis, catalyzing the
dephosphorylation of phosphatidic acid (PA) to form diacylglycerol
(DAG), which is required for the de novo synthesis of phosphatidyleth-
anolamine (PE), phosphatidylcholine (PC) and triglycerides (TG)
Fig. 1. Schematic diagram of pathways involving PAP and GPI in mammalian cells. GPI
catalyzes the reversible conversion of G6P to F6P in the second step of glycolysis. We
previously described three GPI-deﬁcientmutant cell lines that also presented deﬁciencies in
PAPactivity [5]. Thisactivity is required for thedephosphorylationofPA to supplyDAGin the
de novo biosynthesis of PC, PE and TG. As a result, the mutant cell lines presented a severe
reduction in the synthesis of PC, PE and TG, accompanied by an accumulation of PA andG3P
with no changes in the synthesis of PI (synthesized independently of PAP). The exact nature
of the relationship between GPI and PAP is not yet understood. Abbreviations: GPI, glucose-
6-phosphate isomerase; G6P, glucose-6-phosphate; F6P, fructose-6-phosphate; PAP,
phosphatidate phosphatase; G3P, glycerol-3-phosphate; PA, phosphatidic acid; LPA,
lysophosphatidic acid; DAG, diacylglycerol; CDP-DAG, CDP-diacylglycerol; PI, phosphatidy-
linositol; PC, phosphatidylcholine; PE, phosphatidylethanolamine; TG, triglycerides; Pi,
inorganic phosphate.
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1, Lpin2,and Lpin3) [6,7]whichsharehigh sequence identity andbelong
to the HAD superfamily of phosphatases. All lipins contain a nuclear
localization signal (NLS), which targets certain isoforms to the nucleus
[8]. It is thought that these proteins have dual functionality [9]; in the
cytoplasm they act as phosphatases involved in glycerolipid biosynthe-
sis [7], while in the nucleus they are co-transcriptional factors, binding
tomembers of thePPAR family aswell as other nuclear receptors suchas
hepatocyte nuclear factor 4α, estrogen receptor α and the glucocorti-
coid receptor [9].
Of the lipins, lipin 1 is the most studied. Lipin 1 is expressed as two
alternative splice isoforms, lipin 1α and lipin 1β. Lipin 1α localizes
mainly to the nucleus, while lipin 1β, which has an extra 33–37 amino
acid insert and is targeted almost exclusively to the cytoplasm [10,11].
PAP/lipin 1 localization and activity are regulated through phosphory-
lation, with at least 19 phosphorylation sites identiﬁed by mass
spectrometry [10]. It is likely that hyperphosphorylation, due to mTOR
signaling, results in lipin 1α not localizing to thenucleus and lipin 1βnot
associatingwithmembranes,where its substrate is locatedand synthesis
of glycerolipids occurs [12]. Phosphorylation of lipin 1hasbeen shown to
occur in a rapamycin-inhibitable manner [12,13], implicating themTOR
complex in the regulation of lipin 1 [10,12,13].
Similar to GPI deﬁciencies, inborn errors in lipin genes result in
pathologies in humans andmice. For example, a point mutation in lipin
1 causes a severe lipodystrophy and neuropathies due to a demyeliza-
tion in the homozygous mutant mice [14,15] as well as myopathies in
children due to an alteration in the phospholipid composition of the
skeletal muscle ﬁber membranes [16]. Mutations in the lipin 2 gene are
the cause of severe anemia in Majeed Syndrome [17].
In the present study we describe the cloning of lipin 1α and lipin
1β from the wild-type CHO cell line. We examined the subcellular
distribution and effect of expression of these isozymes in the parent
and GPI-deﬁcient CHO strains. We found that GPI-deﬁcient cells
mislocalized lipin 1α to the cytosol, presented an abnormal, activated
mTOR signaling pathway and were hypersensitive to glucose.
Altogether, the data presented here serves to explain the dependency
of PAP activity on GPI and sheds light on the mechanism of the
pathophysiological state of GPI-deﬁcient cells and the variability in
the degree of severity of the symptoms in GPI-deﬁcient patients.2. Material and methods
2.1. Materials
32
P-inorganic phosphate (
32
Pi) was obtained from Perkin Elmer/
New England Nuclear. Lipids were purchased from Avanti Polar Lipids.
Silica gel G and silica gel 60 thin-layer chromatography plates (EMD),
Ham's F12 and DMEMmedium (Cellgro or Gibco), fetal bovine serum
(HyClone) and tissue culture dishes were obtained from Fisher
Scientiﬁc. Antibodies were purchased from Cell Signaling with the
exception of anti-actin (catalog no. MS-1295, Thermo Scientiﬁc). All
other reagents, unless otherwise speciﬁed, were purchased from
Sigma-Aldrich.
2.2. Cell lines and cell culture conditions
If not speciﬁed otherwise, cells were maintained in Ham's F12
medium supplemented with 10% fetal bovine serum, 1 mM gluta-
mine, penicillin G (100 U/ml) and streptomycin (75 U/ml). Cells were
cultured at 33 °C or 40 °C using 5% CO2. Cell lines used were ZR-82
[18], a peroxisome-deﬁcient strain derived from wild-type CHO-K1;
GroD1, a GPI mutant and glycerolipid deﬁcient cell line derived from
ZR-82 [5]; and, GroD1t(GPI) a stable GroD1 cell population expressing
wild-type hamster GPI [5].
2.3. Cloning and sequencing of hamster lipin 1
Total RNAwas isolated from cells with the RNeasy kit (Qiagen) and
ﬁrst strand synthesis of RNA was performed with SuperScript III
reverse transcriptase (Invitrogen). Hamster lipin 1 was cloned from
CHO-K1, ZR-82 and GroD1 cells from total cDNA using primers
designed for regions of high homology among known lipin cDNA's at
either end of the cDNA; forward 5′ ATG AAT TAC GTG GGG CAG 3’ and
reverse primer 5′ CCA GGG TCC CCA CAA CCT ATC CTT TAA T 3’. Once
the PCR product was obtained, the initial sequences were obtained
with primers used to generate the PCR product. As new sequences for
hamster lipin 1 were obtained, new primers were designed to
sequence the entire cDNA. Digestion of the β isoform from the PCR
product was performed with Ale I (New England Biolabs) to allow
sequencing of lipin 1α. CHO-K1 lipin 1α and lipin 1βwere cloned into
the pSC vector using a blunt PCR cloning kit from Stratagene. cDNA
sequences for hamster lipin 1β beta and lipin 1α were submitted to
the NHI GenBank sequence database, accession numbers GU474204
and GU474205 respectively.
2.4. Expression of hamster lipin 1
For stable mammalian expression, lipin 1 was cloned using the
forwardprimer5′GTTGTTGAATTCCACCAATGAATTACGTGGGGCAGT
T 3′ and reverse primer 5′GTT GTT GAA TTC AGT GGT GAT GGT GAT GAT
GAG CTG AGG CTG AAT TGT ACG T 3′ and inserted as an EcoRI fragment
into the pBABEpuro vector [19] to generate pBABE(Lpin1α)puro and
pBABE(Lpin1β)puro vectors. HEK293T cells were co-transfected with
helper virus pCL-10A1 (Imgenex) and pBABEpuro vectors, using Fugene
6 (Roche) to produce supernatant rich in non-replicative retroviral
particles. Cells were infected for 3 h with virus containing supernatant
in the presence of 10 μl/ml polybrene. Medium was changed to Ham's
F12 containing 10% FBS and 6 μg/ml puromycin 24 h post infection.
2.5. Phospholipid biosynthesis
For phospholipid biosynthesis, short-term labeling with
32
Pi was
used. Cells were plated into six well tissue culture plates (2.5×105cell/
well) and allowed to attach overnight at 33 °C. The next day, vials were
placed at 40 °C for 2 h, medium was then changed to growth medium
containing
32
Pi (20–50 μCi/ml) and incubated for 2.5 to 3 h at 40 °C.
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the linear range for
32
P-labeling of phospholipids in CHO cells [18].
Medium was removed and lipids were extracted accordingly to the
method of Bligh and Dyer [20] in the presence of 300 μg carrier lipid
(total bovine heart extract). An aliquot was taken to determine total
chloroform-soluble radioactivity. Phospholipidswere separatedby two-
dimensional thin-layer chromatography (2D TLC) using silica gel 60
plates as described [5]. Individual phospholipid species were located by
autoradiography and co-migration with authentic standards. Radioac-
tive bands were scraped and radioactivity was quantitated using liquid
scintillation spectrometry. Parallel, unlabeled wells were used for
protein determinations.
2.6. Measurement of neutral lipid levels
Cells were plated in 100 mm diameter tissue culture dishes at
106 cells/dish and allowed to attach overnight at 33 °C. The next
morning, themediumwas changed to Ham's F12media containing 10%
FBS and 100 μM oleic acid (2:1 FA:albumin ratio). Cells were grown at
37 °C for 48 h after which they were harvested with trypsin,
resuspended in PBS and lipids were extracted as described above.
Neutral lipids were separated using single dimension TLC on silica gel G
plates using hexane:ethyl ether:acetic acid (70:30:1; v/v) as the
development system. Plates were charred on a hot plate after spraying
the plate with 50% sulfuric acid. Charred plates were scanned and the
densities of the bands of interest were determined using the National
Institute of Health ImageJ program [21]. Quantitationwas performed by
comparison to standard curve for eachneutral lipid class, run in adjacent
lanes on the same TLC plate.
2.7. Phosphatidate phosphatase activity assay
PAP activity was measured in the soluble fraction of whole-cell
homogenates obtained by ultracentrifugation of a sonicated lysate [5].
[
32
P]PA was synthesized enzymatically, using diacylglycerol kinase,
diolein and [γ-
32
P]ATP as described previously [22]. PAP activity was
measured by following the release of water-soluble
32
Pi from
chloroform-soluble [
32
P]PA for 20 min at 37 °C. The reaction mix
contained 50 mM Tris-maleate buffer (pH 7.0), 2 mM MgCl2, 0.1 mM
[
32
P]PA (10,000 cpm/nmol), 0.5 mM trition X-100, and cellular protein
(~25 μg) in a total volume of 0.1 ml. Mg2+-dependent PAP activity
represents the difference in activity obtained with or without the
addition of 5 mM EDTA to the assay mixture. All enzyme assays were
conducted in triplicate and were linear with time and protein
concentration.
2.8. Fluorescence localization of lipin 1
Hamster lipin 1 isoforms were cloned into the pcDNA3.1-Ct-GFP
vectorusing the TOPOTAcloningkit (Invitrogen). The forwardprimer 5′
GACCAT GAA TACGTGGGGCAG3’ and reverse primer 5′ CTGAGG CAG
AAT GA TGT CC ′3were used. Sequence directionality and correct frame
sequence with GFPwere veriﬁed by sequencing. This results in a GFP at
the carboxy terminus of the lipin 1 polypeptide. Cells (105 cells/dish)
were plated into 35-mm diameter poly-d-lysine glass cover (No. 1.0)
bottom tissue culture dishes (catalog no. P35GC-1-14-C, MatTek
Corporation) in 2 ml of Ham's F12 media containing 10% FBS. The next
day, cellswere transfectedwith 2 μgof plasmidDNAand6 μl of Fugene6
(Roche) following the manufacturer's protocol. For some samples,
medium was switched 4 h after transfection to medium containing
50 nM rapamycin or 30% FBS and 4 mM glucose. Cells were observed
24 h post-transfection with a Nikon deconvolution inverted epiﬂour-
escent microscope. Just prior to observation, Hoechst 33342 (Invitro-
gen) ﬂuorescent nuclear stain (ﬁnal concentration of 0.1 μg/ml) was
added.2.9. Coomassie blue staining of colonies
Cell growth was visualized by staining cell colonies with
Coomassie blue [23]. Brieﬂy, cells were plated at low density (500
cells/well) in 24-well dishes and grown for 12 to 14 days in the
speciﬁed medium. Medium was removed, cells were rinsed twice
with PBS (phosphate-buffered saline), then stained with 0.5%
Coomassie blue in methanol: water: acetic acid (45:45:10; v/v) for
1 h, followed by three washes of 10 min each with methanol: water:
acetic acid (45:45:10; v/v) and allowed to dry prior to digitalization of
the plates using a commercial desktop scanner.2.10. Measurement of glucose-6-phosphate and fructose-6-phosphate
levels
Cellular glucose-6-phosphate (G6P) and fructose-6-phosphate
(F6P) levels were measured enzymatically by measuring NADPH
ﬂuorescence as described by Lang and Michal [24]. Brieﬂy, cells from
ﬁve conﬂuent 100 mm diameter dishes were harvested with trypsin
and pelleted by centrifugation at 1000×g for 5 min. Metabolites were
then extracted on ice with 1 ml of 0.8% perchloric acid. The extraction
was neutralized with 10 M KOH to pH 7 and 500 μl aliquots were
assayed. The ﬁnal assayed contained 0.2 N triethanolamine buffer (pH
7.5), 5 mMMgCl2, 20 μMNADP+ in a ﬁnal volume of 1 ml. Glucose-6-
phosphate dehydrogenase (0.06 units) was added to measure
glucose-6-phosphate. After complete depletion of G6P in the sample,
0.035 units of commercial glucose-6-phosphate isomerase was added
to measure fructose-6-phosphate. Known concentrations of either
G6P or F6P were added to the samples to allow for quantiﬁcation.2.11. SDS PAGE and Western blotting
Cells were plated in 6 well plates at 80,000 cells/well in 2 ml of
medium and allowed to attach overnight at 33 °C. The next day cells
were shifted to 40 °C for 24 h. Cells were then washed with ice-cold
PBS and lysed in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl,
0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40) in the presence of
Halt protease and phosphatase inhibitor cocktail (Thermo Fischer
Scientiﬁc). Samples were resolved by electrophoresis using a 9% SDS-
PAGE and electro-transferred onto a polyvinylidene diﬂuoride
membranes overnight. Membranes were blocked in 5% non-fat milk
in TBST (20 mM Tris-HCl, pH 8.5, 150 mM NaCl, 0.5% Tween) at room
temperature for 2 h. Blots were incubated at 4 °C with primary
antibody (1:1000) overnight in 5% bovine serum albumin in TBST.
Membranes were washed three times for 15 min in TBST followed by
incubation with the appropriate horse radish peroxidases-couple
secondary antibody (catalog no. AP123P, Chemicon) for 1 h at room
temperature. Membranes were washed and visualized with enhanced
chemiluminescent reagent (ECL, Thermo Scientiﬁc) and X-ray ﬁlm.
Membranes were subsequently stripped using Restore Western
Stripping Solution (Thermos Scientiﬁc) or by incubating membranes
with 50 mMTris-HCl pH 6.8, 2% SDS and 0.71 M β-mercaptoethanol at
50–60 °C 30 min and then re-probed for loading controls as indicated.
Radiograph signal intensities were quantiﬁed using the National
Institute of Health ImageJ software [21].2.12. Lipin 1β gel shift
Cells were transfected with the lipin 1β-GFP construct used for
ﬂuorescent lipin 1 localization experiments described above. After
48 h, cell lysates were resolved on a 10% acrylamide TXG gel (Biorad)
at 200 volts for 2 to 3 h, electro-transferred to a membrane which was
probed using primary antibody against GFP (Invitrogen) as described
above.
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Protein determinations were performed using the BCA kit and
Coomassie protein assay reagent (Thermo Fisher Scientiﬁc).
2.14. Statistical analysis
For comparison of multiple samples ANOVA, followed by Tukey's
HSD multiple comparison procedure was performed. Two-tailed
Student's t-tests were performed when comparing two samples.
Values of P≤0.05 were considered signiﬁcant differences.
3. Results
3.1. Cloning and sequencing of hamster lipin 1α and lipin 1β
Loss of GPI activity in mutants previously reported by this
laboratory resulted in decreased PAP activity and greatly reduced
glycerolipid biosynthesis [5]. We wanted to test if we could overcome
this glycerolipid biosynthetic deﬁciency in the GPI deﬁcient mutants
by overexpression of either lipin 1α or lipin 1β. We cloned and
sequenced hamster lipin 1 in these cells using primers designed to
regions of high identity with known lipin 1 cDNA sequences from
other species. Initial sequencing was performed using PCR products
obtained from total RNA isolated from wild-type CHO-K1 cells.
Homology alignment identiﬁed this sequence as the lipin 1β isoform
(Lpin 1β, GenBank accession no. GU474204) (Fig. 2). Since sequences
were obtained from PCR products, this suggests that lipin 1β is the
major form of lipin 1 in CHO-K1 cells.Fig. 2. Sequence and features of hamster lipin 1. Top panel: Amino acid sequence of Chinese h
and C-terminal lipin domains as determined by homologywith other known lipin sequences;
insert of 39 amino acids. Lower panel: Alignment of the new sequence with respect to know
sequences.Minor sequencing chromatogram peaks at the beginning of the
beta β-insert suggested the presence of another isoform being
expressed in lower abundance in CHO-K1. The β-insert contains a
unique Ale I restriction site. Therefore, we treated our PCR product
with this endonuclease to speciﬁcally digest the beta isoform. Gel
puriﬁcation of the digest-resistant DNA allowed us to clone and
sequence the Lpin 1α isoform (GenBank accession no. GU474205).
Similar to the lipin 1β from other species, hamster lipin 1β
contained an additional insert of 39 amino acids (β-insert; Fig. 2)
when compared to the lipin 1α isoform. The hamster lipin 1 displayed
high identity with lipin 1 sequences from mouse (93.8%), rat (94.4%)
and human (89.5%). It contained all the features found in the lipin
family (Fig. 2) including the NLS signal, the HAD-like domain and two
highly homologous regions known as N-terminal and C-terminal lipin
domains (NLIP and CLIP). However, some features distinct to the
hamster sequence were also found. The beta insert is slightly longer,
by seven amino acids, compared to mouse and rat (Fig. 2). All of the
nineteen residues, identiﬁed by mass spectrometry to be phosphor-
ylated in mouse lipin 1 [12], were retained in the hamster sequence
except for Ser-392, which is a leucine residue. This residue is also
replaced by a leucine for the human form of lipin 1, indicating perhaps
that the phosphorylation of Ser-392 is not of importance for the
regulation of lipin 1.
Like the CHO-K1 cells, cloning and sequencing of hamster lipin 1
from the cell lines ZR-82 and GroD1 also suggested that lipin 1β was
the most abundant alternative spliced isoform for these cells.
Sequencing of both lipin 1α and lipin 1β from the GPI-deﬁcient
mutant, GroD1, showed 100% identity with the CHO-K1 sequence,
demonstrating that there were no mutations associated with the lipin
1α or lipin 1β cDNA in this cell line.amster lipin 1β. Arrows and colors indicate protein features: NLIP and CLIP, N-terminal
NLS, nuclear localization sequence; HAD (haloacid dehalogenase)-likemotif; In gold, β-
n lipin 1 at the beta-insert region showing the high identity and similarities between
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vitro PAP activity, but does not correct the glycerolipid biosynthetic
deﬁciency
To test if the overexpression of hamster lipin 1 could revert the
phenotype observed in GroD1 cells (i.e., deﬁciency in PAP activity,
reduced glycerolipid biosynthesis and temperature-sensitive growth
phenotype) we stably expressed hamster lipin 1α and lipin 1β in the
mutant cell line, GroD1 and the parent cell line ZR-82 using the
retroviral vector pBABEpuro [19]. After selection with puromycin, we
examined the surviving population for expression of hamster lipin 1
by assaying PAP activity in the soluble fraction of lysed cells. Cells
transfected with lipin 1α and lipin 1β displayed approximately a 6-
fold higher PAP activity than the activity normally found in ZR-82 cells
(Fig. 3A).
Despite the higher PAP activity in these cells, overexpression of
either lipin 1α or 1β did not revert the temperature sensitive growth
phenotype of GroD1 (Fig. 3B). Phospholipid synthesis, assessed using
short-term
32
Pi incorporation into phospholipids [5], showed that ZR-
82 overexpressing lipin 1α (ZR-82t(Lpin1α)) presented higher
32
Pi
incorporation into phospholipids (Fig. 4A), primarily due to a 1.4-fold
increase in PC labeling. This was accompanied by a statistically
signiﬁcant decrease in PA, PI and PG labeling. ZR-82 cells over-
expressing lipin 1β (ZR-82t(Lpin1β)) did not present any signiﬁcant
differences compared to uninfected ZR-82 cells with respect to
32
Pi
labeling. For GroD1 cells, overexpression of either lipin 1 isoform
(GroD1t(Lpin1α) and GroD1t(Lpin1β)) did not change the incorporation of
32
Pi into the general phospholipid pool. There was only a minor (b15%),
but statistically signiﬁcant, increase in PC labeling in GroD1t(Lpin1α) cells
compared to uninfected GroD1 cells (Fig. 4B).
Since CHO cells do not accumulate signiﬁcant triglyceride levels
under normal growth conditions, we supplemented the medium with
100 μM oleic acid to force their accumulation. While an increase in
triglyceride levels in cells may reﬂect an increase in synthesis or a
decrease in lipolysis or both, the accumulation of triglycerides in cells
indicates a shift favoring synthesis. When ZR-82 cells were grown for
2 days under these conditions they accumulated triglycerides (Fig. 4C).
Infection of these cells with either lipin 1α or lipin 1β was unable to
affect the levels of neutral lipids. When grown under the sameFig. 3. PAP activity and cell growth in ZR-82 and GroD1 cells expressing lipin 1 isoforms.
Cells stably expressing hamster lipin 1α, superscript t(Lpin1α), or lipin 1β, superscript t
(Lpin1β), were engineered using retroviral constructs as described in Material and
methods. (A) PAP activity was measured as Mg2+-dependent release of water-soluble
32
Pi from chloroform-soluble [
32
P]PA in soluble cell fractions [22]. (B) Cells stably
expressing lipin 1 isoforms were plated at 3×104 cells/well in six well plates and grown
at 40 °C for 10 days, followed by staining with Coomassie blue. Graph values represent
the average±standard deviation of three independent experiments. *Indicates a
P≤0.05 that the value for each cell infected with either lipin 1 isoform is the same the
value obtain by infecting the same cell with an empty vector.conditions, GroD1 cells accumulated much less triglyceride than ZR-
82 cells (Fig. 4D). Instead, their cholesterol ester levels were enhanced
roughly two-fold over those of the parent strain. GroD1t(Lpin1α)
contained about 10% less cholesterol esters compared to cells infected
with the vector only (GroD1t(Puro)). No statistically signiﬁcant differ-
ences were observed for other glycerolipids assayed in GroD1 cells
expressing hamster lipin 1α or lipin 1β (Fig. 4B and D).
In summary, overexpression of lipin 1 isoforms in GroD1 increased
PAP activity measured in the soluble fraction of cell homogenates, but
had no dramatic effect on glycerolipid synthesis. Taken together this
strongly supports the notion that, in themutant cell line, themutation
in GPI is the cause of the deﬁciency in glycerolipid biosynthesis, and
this cannot be overcome by increased PAP expression/activity.
3.3. Decreasing glucose and increasing serum levels in the growth
medium restores growth and phospholipid biosynthesis
All of our CHO-derived cell lines are typically grown in Ham's F12
medium, which contains 10 mM glucose and is supplemented with
10% FBS. GroD1 cells display a temperature-sensitive growth
phenotype, their growth ceasing after two doublings at 40 °C [5].
The cause of this growth phenotype was not known. We altered
medium components in an effort to restore growth at 40 °C. Reduction
of glucose levels in the medium with 10% FBS partially rescued GroD1
cells at 40 °Cwithmaximum cell growth between 2 and 4 mMglucose
(Fig. 5A). Increasing FBS levels also had a signiﬁcant effect on cell
growth at the non-permissive temperature, partially rescuing the
GroD1 cells even in the presence of inhibitory levels of glucose
(10 mM). However, increased serum levels failed to recover growth at
25 mM glucose indicating sensitivity to glucose in the GPI-deﬁcient
state.
We measured phospholipid biosynthesis at 40 °C using medium
that yielded optimal growth of GroD1 (6 mM glucose and 30% FBS)
and the normal medium (10 mM glucose and 10% FBS). Using the
optimal growth medium, not only was the incorporation of
32
Pi
labeling into total lipids increased, but the incorporation of label into
PC, PE and PA were also restored nearer to the levels expected of ZR-
82 cells (Fig. 5B).
To explore the reason for the glucose sensitivity we measured the
levels of glucose-6-phosphate (G6P) and fructose-6-phosphate (F6P)
in perchloric acid extracts of GroD1 and ZR-82 cells in order to see if
there was a change in these two glycolytic intermediates, products
and substrates of the reversible reaction catalyzed by GPI. Both cell
lines presented similar levels of F6P (Fig. 5C) however GroD1 cells
accumulated G6P to one order of magnitude higher than ZR-82 cells
(Fig. 5C). This indicates that a new steady state was achieved for these
metabolites in GroD1, with a large accumulation of G6P as a
consequence of the GPI mutation.
3.4. Akt/mTOR signaling in GroD1 and ZR-82 cells
PAP/Lipin 1 has been shown to be under the control of the mTOR
pathway [10]. Furthermore, the mTOR pathway is known to be a
nutrient signaling pathway [25,26]. Hence, we explored the activation
of several members of the Akt/mTOR pathway using Western blot
analysis in cell lysates from ZR-82 and GroD1 cells.
PDK1 is an important mediator of insulin-stimulated mTOR
activation [27]. No statistically signiﬁcant difference was observed
in the phosphorylation level of Ser 241 on PDK1 in lysates from ZR-82
and GroD1 (Fig. 6). However, we found that, in the same lysates,
residue Thr 308 of Akt, a substrate of PDK1, presented higher
phosphorylation levels (about 4-fold) in GroD1 cells compared to
ZR-82. In addition, Akt residue Ser 473 and S6K Thr 389, both speciﬁc
substrates of the mTOR complex [26,27], had increased phosphory-
lation levels in GroD1, about 2-fold over ZR-82. We observed no
differences in the phosphorylation levels of either mTOR, Ser 2482 or
Fig. 4. Effects of over-expression of hamster lipin 1 in ZR-82 and GroD1 cells on glycerolipid synthesis. Cells stably expressing hamster lipin 1α, t(Lpin1α), or lipin 1β, t(Lpin1β), were
engineered using retroviral constructs as describe in Material andMethods. (A) and (B) phospholipid biosynthesis, measured by short-term labeling with
32
Pi (2 h at 40 °C), followed
by 2D-TLC separation and quantiﬁcation by liquid scintillation spectrometry. (C) and (D) Cholesterol ester, triglyceride and cholesterol levels after 48 h in medium supplemented
with 100 μM oleic acid, measured after TLC separation by densitometric quantitation of charred pates. For all graphs, values represent the average±standard deviation of three
independent samples. *Indicates a P≤0.05 that the value is the same as the value obtained from uninfected or vector-alone infected cells.
Fig. 5. Glucose and fetal bovine serum concentrations effects on temperature sensitive growth and phospholipid biosynthesis of GroD1 cells. (A) Coomassie blue colony staining of
GroD1 cells grown in media containing the indicated amounts of glucose and FBS at 40 °C for 14 days. Increasing amounts of FBS, as well as lower concentrations of glucose allowed
GroD1 growth at the restrictive temperatures. (B) Phospholipid biosynthesis of GroD1 cells at the indicated glucose and FBS concentrations. Cells were labeled with
32
Pi for 2 h at
40 °C, lipids were extracted, separated and quantiﬁed as described in Material andMethods. The horizontal bars represent expected values for parent strain ZR-82. All glucose values
took into account the contribution of the fetal bovine serum used to supplement the medium which contains 8 mM glucose. (C) Fluorescent measurement of cellular glucose-6-
phosphate (G6P) and fructose-6-phosphate (F6P) cellular levels. Arrows on the tracing indicate that a bolus of 300 pmol of G6P or F6P standard was added. The addition of G6PDH
and GPI are indicated on the X axis. Insert: Quantitated metabolites levels. All values represent the average±standard deviation of three independent experiments. *Indicates a
P≤0.05 between samples.
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Fig. 6. GPI-deﬁciency results in mTOR substrates hyperphosphorylation. GroD1, ZR-82
and Grod1t(GPI) (GroD1 stably expressing GPI) cells were plated in six well plates
(8×104 cells/well), allowed to attach overnight at 33 °C, then shifted to 40 °C for 24 h.
Cell lysates were collected in RIPA buffer and subject to Western blot analysis using
phospho-speciﬁc antibodies. Densitometry analyses are shown below the blots. Values
represent the averages of three independent experiments. *P≤0.05 between the
indicated samples using Tukey's HSD multiple comparison procedure.
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the phosphorylation levels of other members of the Akt signaling
pathway including PTEN, GSK-3β and cRaf (Table 1). Additionally, we
assayed for activation of AMPK, a Ser/Thr kinase, which senses cellular
energy ATP/AMP levels [28]. We found no increased phosphorylation
of the AMPK α subunit (Table 1).
Altogether, these results suggest that there is a PDK1 independent
activation of the nutrient-signaling mTOR pathway in GroD1 cells
compared to ZR-82. This activation is concomitant with a non-
phosphorylation-mediated activation of the mTOR complex in these
cells.
3.5. GroD1 cells do not localize lipin 1α to the nucleus
As mentioned earlier, all lipin members contain a NLS (nuclear
localization signal). Fluorescence microscopy [8] and immunoﬂuo-
rescence microscopy [11] have shown that lipin 1α is predominantly
present in the nucleus. On the other hand, the alternatively spliced
form, lipin 1β, is mainly cytoplasmic.
We fused GFP to the C-terminus of lipin 1α and lipin 1β and
transfected ZR-82 and GroD1 with these constructs. There was a
signiﬁcant difference in subcellular localization of lipin 1α-GFP when
comparing the two cell lines. For the parent strain, ZR-82, lipin 1α-Table 1
Phosphorylation levels of mTOR, AMPK and other members of the Akt signaling
pathway.
Protein ZR-82
(relative intensity)
GroD1
(relative intensity)
Normalized to
mTOR (Ser 2482) 0.10±0.03 0.12±0.02 Actin
mTOR (Ser 2448) 0.37±0.09 0.47±0.06 Actin
PTEN (Ser 380) 1.1±0.1 1.3±0.2 PTEN (total)
GSK-3β (Ser 9) 1.4±0.6 1.7±0.7 Actin
c-Raf (Ser 258) 4.5±1.0 3.7±0.5 Actin
AMPKα (Thr 178) 6.0±1.2 5.2±0.8 AMPKα (total)
Sampleswere plated into sixwell plates (8×104 cells/well), allowed to attachovernight at
33 °C, then grown at 40 °C for 24 h prior collecting cell lysate in RIPA buffer. Lysates were
subject to Western blot analysis. Values represent average±standard deviation of the
densitometry analysis of three independent samples. No statistically signiﬁcant (P≤0.05)
differences were observed between ZR-82 and GroD1.GFP presented strong ﬂuorescence in the nuclei (Fig. 7A), in
accordance with previous ﬁndings [11]. Strikingly, in GroD1 cells
expressing the lipin 1α-GFP construct most of the ﬂuorescence was
restricted to the cytosol. We quantiﬁed the cellular distribution of
lipin 1α-GFP by analyzing co-localization with the nuclear ﬂuorescent
stain Hoechst. Twenty-four hours post-transfection, 87% of ZR-82 cells
presented ﬂuorescence in their nuclei, while only 23% of GroD1 cells
had the expected ﬂuorescence distribution for lipin 1α (Fig. 7B).
Co-expression of wild-type GPI with the lipin 1α-GFP construct
restored nuclear localization of lipin 1α in GroD1; 76% of these cells
presented nuclear ﬂuorescence. This suggests that the mislocalization
of lipin 1α in GroD1 is a result of the GPI mutation and links abnormal
subcellular localization of lipin 1α to the glycerolipid biosynthesis
deﬁciency observed in the GPI-deﬁcient cell line [5]. As further
evidence that abnormal mTOR activation is preventing lipin 1α from
proper localization in GroD1, we treated cells with the mTOR
inhibitor, rapamycin [10]. This treatment also resulted in lipin 1α
association with the nucleus (Fig. 7B).
To investigate the effects of glucose sensitivity on lipin 1α
localization in GroD1 cells, we grew the cells with medium containing
reduced glucose (4 mM) and 30% FBS, conditions which favored
growth of this cell line at 40 °C. GroD1 cells grown in this medium
showed a signiﬁcant increase in the nuclear localization of lipin 1α
(Fig. 7B).
It is thought that the lipin 1β isoform is directly involved in
glycerolipid biosynthesis ([29,30]). In both ZR-82 and GroD1, the
fusion protein, lipin 1β-GFP displayed a diffuse extranuclear ﬂuores-
cence consistent with a cytoplasmic protein (Fig. 8A). Less than 25% of
the cells from either cell line displayed nuclear ﬂuorescence when
transfected with lipin 1β-GFP (Fig. 8B). It was impossible to tell
whether the lipin 1β-GFP was more, or less membrane-associated in
the GroD1 cells, although the ﬂuorescence in the ZR-82 cells appeared
to be more localized in the perinuclear region. Lipin 1 is also a known
target of mTOR ([10,13,31]) and phosphorylation of lipin 1β prevents
its membrane association and therefore its ability to participate in
glycerolipid synthesis. Western analyses of lysates from cells
transfected with the lipin 1β-GFP fusion construct were run. ZR-82
and GroD1 displayed different migration patterns (Fig. 8C). As
observed previously for lipin 1β ([12,13]), there appeared to be
more than one species of the protein, the slower migrating species
representing the more heavily phosphorylated forms. While the
density was evenly distributed throughout the lipin 1β-GFP species in
the ZR-82 lysates, the dominant species was clearly the slowest
migrating (most phosphorylated) species in GroD1. In fact, we could
ﬁnd no signal that co-migrated with this putatively more phosphory-
lated species in the ZR-82 samples.
4. Discussion
In this study we report the ﬁrst cloning and sequencing of theα and
β splice variants of lipin 1 from Chinese hamster cells. These hamster
isoformswere similar to previously cloned lipin 1α and lipin 1β from rat
[10] and mouse [11] in sequence and in cellular localization for wild-
type cells. Overexpression of either form of hamster lipin 1 in CHO cells
resulted in an increase in a Mg2+-dependent PAP activity, indicating
that these cloned sequences indeed encode an active PAP enzyme. It is
interesting that, while retroviral-mediated expression of lipin 1α and
lipin 1β in the GPI-deﬁcient cells increased in-vitro PAP activity, it failed
to restore TG accumulation and phospholipid biosynthesis in this
mutant cell line. (Fig. 4). This conﬁrms a pleiotropic effect of the GPI
mutation or loss of GPI activity on PAP cellular activity. We have ruled
out that the nature of this effect on the suppression of glycerolipid
biosynthesis is related to an impairment of glycolysis, per se, since we
have previously reported no reduction in ATP levels or glycerol-3-
phosphate levels in the GPI mutant cell line [5]. Furthermore, we have
shown that levels of the glycolyticmetabolite F6P and phosphoAMPK, a
Fig. 7. GPI deﬁciency induces an altered lipin 1 subcellular localization dependent of the mTOR pathway and glucose/FBS media concentration. Cells were transfected with a
mammalian expression vector containing human lipin 1α-GFP fusion protein. (A) Live cell images taken with a Nikon deconvolution epiﬂuorescence microscope 24 h post-
transfection. In blue, Hoechst ﬂuorescent nuclear stain; in green, GFP ﬂuorescence. Fluorescent images were overlaid onto a bright ﬁeld image. (B) Quantitation of the cellular
localization of human lipin 1α-GFP construct in ZR-82, GroD1, GroD1t(GPI) (GroD1 cell stably expressing wild-type GPI), as well as GroD1 cell grown in media with low glucose and
high FBS or treated with 50 nM rapamycin. Each experimental condition involved analysis of over 100 cells/strain. The data bars represent the mean of three such experiments, +/−
one standard deviation. All differ signiﬁcantly from GroD1 under standard conditions (*Pb0.05).
Fig. 8. Cellular localization of lipin 1β in ZR-82 and GroD1 cells. Cells were transfected with a mammalian expression vector containing human lipin 1β-GFP fusion protein. (A) Live
cell images taken with a Nikon deconvolution epiﬂuorescence microscope 24 h post-transfection. In blue, Hoechst ﬂuorescent nuclear stain; in green, GFP ﬂuorescence. Fluorescent
images were overlaid onto a bright ﬁeld image. (B) Quantitation of the cellular localization of human lipin 1β-GFP construct. (C) Western analysis performed on cell lysates using
antibody to GFP as described in Materials and Methods. The arrow head on the right indicates the putative hyperphosphorylated lipin 1β-GFP species. All experiments were
conducted three separate times with similar results. Values represent the average±standard deviation of three independent experiments; each experiment involved the analysis of
over 100 cells/strain. No statistically signiﬁcant difference (P≤0.05) was observed or ZR-82 and GroD1 cells.
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Fig. 9. Schematic diagram depicting the possible pathophysiological state of GPI-
deﬁcient GroD1 cells. The ﬁgure shows the canonical insulin/mTOR regulation of lipin 1
[10,13]. The GPI deﬁcient cell, GroD1, accumulates G6P, a putative activator of mTOR
[36]. An activated mTOR leads to cytosolic localization of lipin 1 [13]. No longer
associated with membranes and away from it substrate, lipin 1 is inefﬁcient for
lipogenic synthesis. The GPI-deﬁcient cells develop glycerolipid deﬁciency with
accumulation of PA, another activator of mTOR [37]. Thus, exacerbating the mTOR
activation. Gray arrows indicate the observation found in GroD1 cells compared to ZR-
82 cells (i.e. high levels of PA and G6P, increase in phosphorylation of mTOR substrates,
Akt(Ser473) and S6K(Thr389), and cytosolic presence of lipin 1).
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in the mutant GroD1 when compared to the parent cell line, ZR-82.
Our evidence suggests that the reduced glycerolipid biosynthesis is
a result of an abnormal activation of the nutrient signaling mTOR
pathway. In order for PAP/lipin 1 to be lipogenically active, it must
associate with membranes since this is where its substrate, PA, is
located [12,32–34]. It has been previously demonstrated that
activation of mTOR results in phosphorylation of lipin 1 [10,13,35],
resulting in the sequestration of lipin 1 in the cytosol [12], thus
preventing PAP access to the nucleus and membranes. Additionally,
inhibition of the mTOR pathway results in membrane-association and
nuclear localization of PAP/Lipin 1 [12,13]. Abnormal activation of the
mTOR pathway would explain the altered subcellular distribution of
lipin 1α and reduced glycerolipid biosynthesis in GroD1, as well as the
observed increase in phosphorylated mTOR targets, S6K(Ser 389) and
Akt(Ser 473) [26,27]. Furthermore, treatment of mutant cells with
rapamycin, a well established inhibitor of the mTOR complex, [10]
reverts the nuclear localization of lipin 1α. This is consistent with the
notion that altered subcellular localization is a consequence of the
overactivated mTOR signaling.
While lipin 1α appears to function in the nucleus as a transcription
factor it is lipin 1β that is thought to be involved in glycerolipid synthesis
functioning as a PAP [29]. Association with the membrane (e.g. the
endoplasmic reticulum) would be required for effectiveness of this
protein. Consistentwith this are reports that PAPactivityhas been found
to associate with membranes under conditions that increase glycer-
olipid synthesis [34]. Although theﬂuorescenceassociatedwith the lipin
1β-GFP fusion construct appeared to have a diffuse distribution pattern
in both the parent strain and GroD1, the ﬂuorescence in the ZR-82 cells
appeared to bemore localized in the perinuclear region, consistentwith
anassociationwith theendoplasmic reticulum.Consistently,wedidﬁnd
evidence that lipin 1β is hyperphosphorylated in the mutant cells.
The GPI-deﬁciency resulted in accumulation of high levels of G6P, a
metabolite described as an activator of themTOR signaling pathway in
isolated cardiomiocytes [36]. In addition, growth of GroD1 cells in
reduced glucose medium or retroviral expression of wild-type GPI,
two situations that would lower cellular levels of G6P, result in
reversion of the lipogenic deﬁcient phenotype and the abnormal
subcellular localization of lipin 1α. Hence, an activated mTOR
nutrient-signaling pathway, due to the accumulation of G6P, might
explain the observed phenotype in GroD1 cells. Additionally, the GPI
deﬁciency in these cells increased PA levels [5]. PA is a well
established activator the mTOR signaling pathway [37]. Thus, the
initial effects of G6P on mTOR activity would be exacerbated as
glycerolipid biosynthesis is impaired and PA accumulates in these
cells (Fig. 9).
These results have relevance to symptoms associated with human
GPI deﬁciency. Patients with GPI deﬁciency present different degrees
of non-spherocytic hemolytic anemia (NSHA). In some cases, these
patients manifest neuromuscular dysfunctions characterized by
muscle weakness and mental retardation [2,38–43]. The molecular
basis for these symptoms has not been established [2]. There are 29
identiﬁed GPI mutations that cause NSHA. In all cases in which G6P
levels were assayed, increased levels of this metabolite were found in
red blood cells as well as in muscle and brain tissue [1,4].
Different NSHA patients present different degrees of hemolytic
anemia [1]. However, the degree of the GPI deﬁciency does not
correlate well with the severity of the anemia. For example, some
patients with 60% of normal GPI activity display severe anemia [1]
while patients with only 9% residual activity present with a mild to
moderate anemia [44]. Interestingly, homozygous patients with the
same mutation, display the same reduction in GPI activity, but display
different severities of anemia [1] as well as varying degrees of
neurological and muscular dysfunction [3]. Hence, it has been
proposed that there must be either secondary genetic inﬂuences or
environmental factors involved in the severity of the symptomsassociated with NSHA disease [1]. Perhaps our observation with
respect to the glucose-dependent growth inhibition and the observed
G6P accumulation may help to explain the differences in the severity
in human patients andmight warrant future in vivo studies to test the
hypothesis that altering metabolite levels in patients with inherited
GPI deﬁciency could alleviate the severity of symptoms.
It is interesting to note that similar symptoms are associated with
GPI deﬁciencies and lipin mutations. For instance, GPI-deﬁcient
patients can present with mental retardation and neurological
impairment that affects the brain and the spinal cord [38–43,45].
Similarly, lipin 1 mutant mice present peripheral neuropathies
accompanied by demyelination, mediated by PA accumulation in
Schwann cells [14,15]. Additionally, while human patients with lipin 1
mutations manifest generalized muscular hypotonia due to an
alteration in the phospholipid composition of the skeletal muscle
ﬁbers [16], similar symptoms are present in human patients with the
“GPI Homburg” mutation, which results in muscle weakness with
histologically disproportioned muscle ﬁbers [38]. Finally, “Majeed
Syndrome”, which is due to mutations in lipin 2, is characterized by
recurrent anemia, due to inefﬁciency of the bone marrow to produce
rapidly dividing erythrocyte progenitor cells [17]. Abnormalities in
the red blood cell membrane lipid composition have been reported in
inherited erythrocyte metabolic disorders [46]. Alteration in the
membrane lipid composition should compromise cell permeability
and viability. Hence, it is conceivable that the traits observed in our
GPI-deﬁcient cells might help explain some of the manifestations
observed in GPI deﬁcient mice and human patients. The neuromus-
cular abnormalities and the anemia could be caused by dysfunction in
lipid biosynthesis, a hypothesis that needs to be examined in the
future.
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In summary, we report, for the ﬁrst time, a pathophysiological
state, GPI deﬁciency, in which a mutation in a glycolytic enzyme
results in glucose sensitivity and a constitutive activation of the
nutrient signaling mTOR pathway. Such a situation results in
abnormal distribution of the lipin 1α, and possibly lipin 1β, proteins
important for glycerolipid biosynthesis. These ﬁndings highlight the
metabolic communication between glucose and lipid metabolism and
are consistent with the known mechanism for the crosstalk between
these two pathways. They may also explain some of the symptoms
associated with inherited GPI deﬁciency, the variable severity of
symptoms displayed by these patients and importantly, may offer
new therapies.
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